公开(公告)号：US20130189676A1

公开(公告)日：2013-07-25

申请号：US13666606

申请日：2012-11-01

Applicant: Universitat Duisburg-Essen

Inventor： Kathrin Riemann ,  Winfried Siffert

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/172

Abstract: The invention relates to an in vitro method for predicting disease risks, progression of diseases, drug risks, success of treatment and for finding drug targets by looking for one or more genetic modifications in the promoter region of the CHK1 (CHEK1) gene on human chromosome 11q23, the genetic modifications being a substitution thymine for guanine in position −1143 in the promoter of CHK1, of thymine for cytosine in position −1400, a substitution of cytosine for thymine in position −1453 or an insertion of one cytosine in position −1454 and the genetic modifications being detected individually or in any combinations by way of known methods.

Abstract translation: 本发明涉及通过在人染色体上寻找CHK1（CHEK1）基因的启动子区域中的一种或多种遗传修饰来预测疾病风险，疾病进展，药物风险，治疗成功和寻找药物靶标的体外方法 11q23，遗传修饰是在CHK1启动子中位置-1143处鸟嘌呤的替代胸腺嘧啶，-1400位的胞嘧啶的胸腺嘧啶，-1453位置中的胞嘧啶取代胸腺嘧啶或-1454位置插入一个胞嘧啶 并且通过已知方法单独或以任何组合检测遗传修饰。

公开(公告)号：US20180177590A1

公开(公告)日：2018-06-28

申请号：US15573455

申请日：2016-05-10

Applicant: Universitat Duisburg-Essen ,  coramaze technologies GmbH

Inventor： Niklas Maximilian NATHE ,  Till NEUMANN ,  Torsten SCHEUERMANN

IPC: A61F2/24

Abstract: An implantable device for improving or remedying valvular incompetence, comprising a sealing body and at least one anchoring element (2) fastened thereto, by means of which the sealing body is able to be fastened in the heart, preferably in the atrium of the heart, wherein the sealing body comprises at least one cavity (6), which is also able to be filled with a fluid after implanting the sealing body and preferably not able to be emptied independently, and wherein, furthermore preferably, the sealing body remains expanded with constant volume during the cardiac phases as a result of the filling, characterized in that a plurality of cavities (6) are disposed about a main body (1) of the sealing body lying in the direction of longitudinal extent of the sealing body, or a single cavity (6) surrounds a main body (1) of the sealing body lying in the direction of longitudinal extent of the sealing body, wherein the main body (1) is embodied as a tube which is able to be bent out of the linear extent thereof and into the lateral surface of which a multiplicity of cuts have been introduced.

公开(公告)号：US11056887B2

公开(公告)日：2021-07-06

申请号：US15737029

申请日：2016-06-16

Applicant: UNIVERSITAT DUISBURG-ESSEN

Inventor： Christian Derksen

IPC: H02J3/38 ,  H02J3/28 ,  H02J3/14 ,  H02J3/32 ,  H02J3/00

Abstract: A distributed energy conversion system is described. The illustrative distributed energy conversion system is described to include a first energy conversion entity and a second energy conversion entity being interconnected via an energy exchange network. The system is further disclosed to include an evaluation entity that is able to communicate with the energy conversion entities and create a roadmap for the consumption of energy by the first energy conversion entity and the second energy conversion entity.

公开(公告)号：US20150337389A1

公开(公告)日：2015-11-26

申请号：US14718755

申请日：2015-05-21

Applicant: Universitat Duisburg-Essen

Inventor： Kathrin Riemann ,  Winfried Siffert

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/172

Abstract: The invention relates to an in vitro method for predicting disease risks, progression of diseases, drug risks, success of treatment and for finding drug targets by looking for one or more genetic modifications in the promoter region of the CHK1 (CHEK1) gene on human chromosome 11q23, the genetic modifications being a substitution thymine for guanine in position −1143 in the promoter of CHK1, of thymine for cytosine in position −1400, a substitution of cytosine for thymine in position −1453 or an insertion of one cytosine in position −1454 and the genetic modifications being detected individually or in any combinations by way of known methods.

Abstract translation: 本发明涉及通过在人染色体上寻找CHK1（CHEK1）基因的启动子区域中的一种或多种遗传修饰来预测疾病风险，疾病进展，药物风险，治疗成功和寻找药物靶标的体外方法 11q23，遗传修饰是在CHK1启动子中位置-1143处鸟嘌呤的替代胸腺嘧啶，-1400位的胞嘧啶的胸腺嘧啶，-1453位置中的胞嘧啶取代胸腺嘧啶或-1454位置插入一个胞嘧啶 并且通过已知方法单独或以任何组合检测遗传修饰。

公开(公告)号：US09074259B2

公开(公告)日：2015-07-07

申请号：US13666606

申请日：2012-11-01

Applicant: UNIVERSITAT DUISBURG-ESSEN

Inventor： Kathrin Riemann ,  Winfried Siffert

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/172

Abstract: The invention relates to an in vitro method for predicting disease risks, progression of diseases, drug risks, success of treatment and for finding drug targets by looking for one or more genetic modifications in the promoter region of the CHK1 (CHEK1) gene on human chromosome 11q23, the genetic modifications being a substitution thymine for guanine in position −1143 in the promoter of CHK1, of thymine for cytosine in position −1400, a substitution of cytosine for thymine in position −1453 or an insertion of one cytosine in position −1454 and the genetic modifications being detected individually or in any combinations by way of known methods.

Abstract translation: 本发明涉及通过在人染色体上寻找CHK1（CHEK1）基因的启动子区域中的一种或多种遗传修饰来预测疾病风险，疾病进展，药物风险，治疗成功和寻找药物靶标的体外方法 11q23，遗传修饰是在CHK1启动子中位置-1143处鸟嘌呤的替代胸腺嘧啶，-1400位的胞嘧啶的胸腺嘧啶，-1453位置中的胞嘧啶取代胸腺嘧啶或-1454位置插入一个胞嘧啶 并且通过已知方法单独或以任何组合检测遗传修饰。

公开(公告)号：US20150125439A1

公开(公告)日：2015-05-07

申请号：US14404881

申请日：2013-05-31

Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ,  YEDA RESEARCH AND DEVELOPMENT CO.LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE ,  UNIVERSITAT DUISBURG-ESSEN

Inventor： Edward H. Schuchman ,  Erich Gulbins ,  Anthony Futerman ,  Yael Pewzner-Jung

IPC: A61K38/50 ,  A61K9/00 ,  A61K45/06

CPC classification number: A61K38/50 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0073 ,  A61K9/12 ,  A61K45/06 ,  C12Y305/01023

Abstract: The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and/or open wound patients.

Abstract translation: 本发明涉及用于治疗或预防患有囊性纤维化，COPD和/或开放性伤口的受试者的病原体感染的方法。 该方法包括选择具有囊性纤维化，COPD和/或开放性伤口的受试者，并在有效减少神经酰胺的病症和治疗或预防病原体感染的条件下向所选受试者施用神经酰胺酶。 该方法还涉及使用神经酰胺酶与其他药物组合以减少感染，减少神经酰胺，或改善囊性纤维化，COPD和/或开放性伤口患者的肺功能。

公开(公告)号：US10411142B2

公开(公告)日：2019-09-10

申请号：US15560544

申请日：2016-03-23

Applicant: UNIVERSITAT DUISBURG-ESSEN

Inventor： Niels Benson ,  Roland Schmechel ,  Marc Hoffmann ,  Thomas Kaiser ,  Daniel Erni

IPC: H01L29/20 ,  H01L29/872 ,  H01L21/268 ,  H01L29/66 ,  H01L29/06 ,  H01L21/02 ,  H01L29/16

Abstract: The invention concerns a method for production of components comprising a Schottky diode by means of printing technology. The method involves a step of application and deposition of a semiconductor-nanoparticle dispersion on a first electrode, which is disposed on a substrate, the step of exposure to laser light of the deposited semiconductor-nanoparticle dispersion to form a mu-cone with a bottom and a tip, wherein the bottom of the mu-cone is joined to the first electrode, the step of embedding the thus-formed mu-cone in an electrically insulating polymer matrix, and the step of applying a second electrode, so that the tip of the mu-cone is joined to the second electrode.

公开(公告)号：US20180133012A1

公开(公告)日：2018-05-17

申请号：US15573454

申请日：2016-05-10

Applicant: Universitat Duisburg-Essen ,  coramaze technologies GmbH

Inventor： Niklas Maximilian NATHE ,  Till NEUMANN ,  Torsten SCHEUERMANN

IPC: A61F2/24

CPC classification number: A61F2/2478 ,  A61F2/2412 ,  A61F2/2454 ,  A61F2/246 ,  A61F2/2463 ,  A61F2210/0014 ,  A61F2220/0008 ,  A61F2220/0016 ,  A61F2220/0075 ,  A61F2230/0004

Abstract: The invention relates to an implantable device for improving or treating a heart valve insufficiency, comprising a closure body (1) and at least one anchoring element fastened thereto, by means of which the closure body (1) can be fastened in the heart, preferably in the atrium of the heart, in which the anchoring element comprises a plurality of contact strips (2) extending between the closure body (1) and a shared connecting element (3) which is spaced from the closure body (1), wherein, due to a shape change of the contact strips (2), the connecting element (3) can be brought into a first and a second position each spaced from the closure body, wherein, in the first position, the connecting element (3) is spaced farther apart from the closure body (1) than in the second position, and in the second position, the connecting element (3) is arranged between the contact strips (2).

公开(公告)号：US20250040825A1

公开(公告)日：2025-02-06

申请号：US18792627

申请日：2024-08-02

Applicant: UNIVERSITAT DUISBURG-ESSEN

Inventor： Mandana JALALI ,  Andreas PROKSCHA ,  Tobias KUBICZEK ,  Jan Taro SVEJDA ,  Sascha PREU ,  Thomas KAISER ,  Jan BALZER ,  Daniel ERNI

IPC: A61B5/0507 ,  A61B5/00 ,  A61B5/145

Abstract: The invention relates to a measuring device for the non-invasive determination of a blood sugar concentration in the body of a mammal, comprising a housing (G), a measuring electronics (IC) in the housing (G), wherein the measuring electronics (IC) further comprises at least one transmitter (Tx) for emitting high-frequency signals with a frequency of more than 0.1 THz and less than 10 THz, at least one receiver (Rx) for receiving high-frequency signals with a frequency of more than 0.1 THz and less than 10 THz, wherein the at least one transmitter (Tx) is designed such that during operation it emits the high-frequency signal via an antenna (ANT_Tx) integrated in the measuring device, wherein the at least one receiver (Rx) is designed such that, during operation, it receives a high-frequency signal via an antenna (ANT_Rx) integrated in the measuring device, wherein the measuring device is configured to be attached relative to a nail plate (NP) on a nail of a finger or toe of the mammal, wherein the high-frequency signals from at least one transmitter (Tx) are coupled through the nail plate (NP) into the nail bed (NB) of the mammal during operation, and wherein the high-frequency signals backscattered from the nail bed (NB) of the mammal through the nail plate (NP) during operation are received by at least one receiver (Rx), wherein the measuring device further comprises an evaluation device (CPU) which is configured to evaluate the backscattered high-frequency signals received by at least one receiver (Rx) in order to determine the blood sugar concentration in the body of a mammal.

公开(公告)号：US20180159332A1

公开(公告)日：2018-06-07

申请号：US15737029

申请日：2016-06-16

Applicant: UNIVERSITAT DUISBURG-ESSEN

Inventor： Christian DERKSEN

IPC: H02J3/38 ,  H02J3/28

CPC classification number: H02J3/381 ,  H02J3/14 ,  H02J3/28 ,  H02J3/32 ,  H02J2003/003 ,  H02J2003/143 ,  H02J2003/146 ,  Y02B70/3225 ,  Y02B70/3266 ,  Y04S20/222 ,  Y04S20/224 ,  Y04S20/242

Abstract: The invention relates to a distributed energy conversion system which includes at least a first energy conversion entity and a second energy conversion entity, with the energy conversion entities being interconnected via an energy exchange network, further including an evaluation entity that is able to communicate with the energy conversion entities.